Abbott and Reckitt unit secure win in infant formula trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Abbott Labs (ABT) PT Raised to $149 at Barclays
November 4, 2024 4:52 AM ESTBarclays analyst Matt Miksic raised the price target on Abbott Labs (NYSE: ABT) to $149.00 (from $143.00) while maintaining a Overweight rating.
The analyst comments "Despite the Upward Move on Friday and 18% Rise Off July Lows, We See More than 25% Upside to Our Target for ABT:... More
